Treadwell Therapeutics is a clinical-stage oncology company developing small molecules, biologics, and T-cell receptor-based therapies targeting novel cancer pathways with limited treatment options. The company aims to create effective medicines that address significant gaps in current cancer therapies through its integrated drug discovery and development capabilities.
Funding
$118M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer therapies often fall short due to limited treatment options and the complex nature of cancer pathways. Many existing treatments do not adequately address the underlying mechanisms driving cancer progression, leaving significant gaps in patient care.
Solution
Treadwell Therapeutics is developing a pipeline of small molecule, biologic, and T-cell receptor (TCR)-based therapies designed to target novel cancer pathways. By integrating drug discovery and development under one roof, Treadwell aims to create first-in-class medicines that overcome limitations of current oncology treatments. The company's approach focuses on identifying and validating new therapeutic targets, then rapidly translating these discoveries into clinical candidates across multiple modalities. This comprehensive strategy allows for a more targeted and effective approach to combating cancer.
Target Audience
The primary target audience includes patients with cancers that have limited treatment options, as well as oncologists and researchers seeking innovative therapies to improve patient outcomes.
Features
- Small molecule inhibitors targeting previously undruggable cancer pathways
- Biologic therapies designed to modulate the immune response to tumors
- T-cell receptor (TCR)-based cell therapies for personalized cancer treatment
- Integrated drug discovery and development engine for rapid translation of research into clinical trials
- Focus on novel targets with limited existing treatment options
- Science-driven approach to identify and validate promising therapeutic targets